C07K 14/095
Rhinovirus
C07K14/095 (Rhinovirus) appears on 7 US grants and 10 published applications in this corpus.
Search patents in C07K- Granted patents
- 7
- Published applications
- 10
- Assignees
- 3
- Inventors
- 8
- Latest grant
- 1 Feb 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 3 |
| 2017 | 0 | 0 |
| 2018 | 2 | 1 |
| 2019 | 2 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
By publication year.
Recent patents
- Re-directed immunotherapy1 Feb 2022US 11,236,131 B2The University of Birmingham
- Immunogenic rhinovirus peptides3 Dec 2019US 10,493,145 B2Glaxosmithkline Biologicals SA
- Re-directed immunotherapy14 May 2019US 10,287,321 B2The University of Birmingham
- Vaccine28 Aug 2018US 10,058,603 B2Glaxosmithkline Biologicals SA
- Immunogenic human rhinovirus (HRV) compositions23 Jan 2018US 9,872,899 B2Biological Mimetics, Inc.
- Immunogenic Human Rhinovirus (HRV) Composition19 Oct 2023US 2023/0330208 A1Biological Mimetics, Inc.
- Immunogenic Human Rhinovirus (HRV) Composition25 Mar 2021US 2021/0085780 A1Biological Mimetics, Inc.
- Re-Directed Immunotherapy5 Sep 2019US 2019/0270779 A1The University of Birmingham
- Immunogenic rhinovirus peptides14 Mar 2019US 2019/0076519 A1Glaxosmithkline Biologicals SA
- Immunogenic Human Rhinovirus (HRV) Composition8 Mar 2018US 2018/0064802 A1Biological Mimetics, Inc.
Most cited
By later US patents
- Re-directed immunotherapy4US 9,402,916 B2The University of Birmingham · 2016
- Immunogenic human rhinovirus (HRV) compositions4US 9,872,899 B2Biological Mimetics, Inc. · 2018
- Re-directed immunotherapy3US 9,358,282 B2The University of Birmingham · 2016
- Re-directed immunotherapy2US 11,236,131 B2The University of Birmingham · 2022
- Re-directed immunotherapy1US 10,287,321 B2The University of Birmingham · 2019